

The European Bronchiectasis Registry

*****IMPORTANT****

We urgently require everyone to complete and submit partially completed cases which are sitting in the unsubmitted section of their CRF accounts.

> This is priority over new recruitment. We cannot analyse data if it is not fully submitted to the registry.

EMBARC will be analyzing the first pan-European data this summer and we are very close to the 10,000 recruitment target.

We cannot emphasize enough how important it is that you are included in this analysis.

Congratulations to Prof.

Highest Recruiters in May



Mordechai Kremer from Rabin Medical Centre in Israel for being this months highest recruiting centre!

Italy for being the highest recruiting country in the registry this month!

Congratulations also to

@EMBARCnetwork Connect with us on



LinkedIn



Please remember to visit EMBARC homepage for links to all the latest publications and news in • regards to our Network members. If you have a recent paper we have not displayed and would like it to be highlighted on the homepage please let us know. If there is anything in particular you

wish to see in the newsletter or online, please do let us know, info@bronchiectasis.eu



September at this years annual congress in Milan. For further information about attending

The new ERS bronchiectasis guidelines will be presented at 14:45 on Sunday 10th

ERS 2017 please visit

www.erscongress.org



The American Thoracic Society was held in Washington DC last month. Here, we saw the results from the two largest randomised controlled trials in bronchiectasis

Promising Future for Bronchiectasis Treatments

completed thus far; RESPIRE 2 and ORBIT 3&4. To read the abstracts please click here

A randomised control trial of Aaorvastatin in bronchiectasis patients infected with Pseudomonas aeruginosa—a proof of concept study

New Publications from the EMBARC Network

AG, Hill AT Chest. 2017 May 26. pii: S0012-3692(17)30966-2. doi: 10.1016/j.chest.2017.05.017. [Epub ahead of

Bedi P, Chalmers JD, Graham C, Clarke A, Donaldson S, Doherty C, Govan JR, Davidson DJ, Rossi

https://www.ncbi.nlm.nih.gov/pubmed/28554732 Investigation of bronchiectasis in severe uncontrolled asthma

Dimakou K, Gousiou A, Toumbis M, Kaponi M, Chrysikos S, Thanos L, Triantafillidou C. Clin Respir J. 2017 May 24. doi: 10.1111/crj.12653. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28544140

Sputum neutrophil elastase as a biomarker for disease activity in bronchiectasis. Brusselle GG, Van Braeckel E. Am J Respir Crit Care Med. 2017 May 15;195(10):1289-1291. doi: 10.1164/rccm.201612-2476ED. No

https://www.ncbi.nlm.nih.gov/pubmed/28504604 The development and validation of the bronchiectasis health related questionnaire.

Cazzola M, Rogliani P, Aliberti S, Blasi F, Matera MG.

abstract available.

Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, Elston C, Loebinger MR, Wilson R, Garrod R, Birring SS Eur Respir J. 2017 May 11;49(5). pii: 1601532. doi: 10.1183/13993003.01532-2016. Print 2017 May. http://erj.ersjournals.com/content/49/5/1601532.long

Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis

An update on the pharmacotherapeutic management of lower respiratory tract infections

Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. Contemp Clin Trials. 2017 May 8;58:78-85. doi: 10.1016/j.cct.2017.05.007. [Epub ahead of print] http://www.sciencedirect.com/science/article/pii/S1551714416304712

The RESPIRE trials: Two phase III, randomised, multicentre, placebo-controlled trials of Ciprofloxacin

of print] http://www.tandfonline.com/doi/abs/10.1080/14656566.2017.1328497?journalCode=ieop20

Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiecta-

Expert Opin Pharmacother. 2017 May 19:1-16. doi: 10.1080/14656566.2017.1328497. [Epub ahead

Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel K, Elborn JS, Walker B, Martin SL, Marshall SE, Huang JT, Fardon TC. Am J Respir Crit Care Med. 2017 May 15;195(10):1384-1393. doi: 10.1164/rccm.201605-1027OC

Fjaellegaard K, Sin MD, Browatzki A, Ulrik CS. Chron Respir Dis. 2017 May;14(2):174-186. doi: 10.1177/1479972316661923. Epub 2016 Aug 9. http://journals.sagepub.com/doi/abs/10.1177/1479972316661923?url_ver=Z39.88-2003&rfr_id=ori% 3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&

- http://www.atsjournals.org/doi/abs/10.1164/rccm.201605-1027OC?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed Antibiotic Therapy for stable non-CF bronchiectasis in adults—a systematic review
- There are still a number of invoices being sent to the wrong address and/or with incorrect details. We cannot stress how important it is to follow the below instructions.

Payment can only be made for cases which have been quality checked and Approved for the registry. You can see which cases have been Approved under the 'status' column on the eCRF. Invoices must be written in English and clearly state a breakdown of how many Baseline cases

***** EU & EU Affiliated Countries*****

- and how many Review cases are being invoiced for as these are costed differently. The billing address must contain University of Dundee Invoices can only be paid to institution accounts and not personal accounts. It is at the discretion
- must first pass through your hospital/University/Department. Please ensure those who raise invoices for your centre are aware of the above information. Delays in payment should be expected when instructions are not followed.

It is the responsibility of each Centre to raise invoices for their recruitment. The central team will not send reminders.

of the centre to how this recruitment payment is spent eg staff payments, however the money

All invoices must be in English and addressed to;

The European Bronchiectasis Registry Clinical Research Centre

> James Arrott Drive **University of Dundee**

> > Ninewells Hospital and Medical School

Dundee DD1 9SY, UK

Alternatively, they can be emailed directly to the study coordinator; m.l.crichton@dundee.ac.uk



